文献速递青光眼

Netarsudil滴眼液长期安全性与降眼压疗效:ROCKET-2研究

Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
PubMed 文献 · Am J Ophthalmol · 2019-01-15

ROCKET-2为双盲随机多中心非劣效研究,纳入756例开角型青光眼或高眼压患者,比较netarsudil 0.02%每日一次、每日两次与噻吗洛尔0.5%每日两次治疗12个月的疗效与安全性。结果显示netarsudil每日一次可有效且持续降低眼压,多数患者可耐受。

要点

  • netarsudil 0.02%每日一次治疗12个月可持续有效降低眼压。
  • 最常见眼部不良事件为结膜充血,发生率61%(每日一次组)。
  • 角膜沉着(角膜垂直纹)发生率26%,未对视觉功能产生临床有意义影响。

核心结论

  • netarsudil 0.02%每日一次可有效且持续降低眼压达12个月,多数患者可耐受。

研究设计与样本

  • 双盲、随机、多中心、平行组、非劣效临床研究,纳入756例开角型青光眼或高眼压患者。
  • 患者随机接受netarsudil 0.02%每日一次(251例)、netarsudil 0.02%每日两次(254例)或噻吗洛尔0.5%每日两次(251例)治疗12个月。
  • 另设非干预性角膜观察研究,针对出现角膜垂直纹的患者。

主要发现

  • 治疗期间上午8点平均眼压从基线22.5-22.6 mmHg降至17.9-18.8 mmHg(netarsudil每日一次)、17.2-18.0 mmHg(netarsudil每日两次)和17.5-17.9 mmHg(噻吗洛尔)。
  • 最常见眼部不良事件为结膜充血,发生率分别为61%(每日一次)、66%(每日两次)和14%(噻吗洛尔)。
  • 角膜沉着(角膜垂直纹)发生率分别为26%、25%和1%;结膜出血(多为点状)发生率分别为20%、19%和1%。
  • 上述三种不良事件总体评分为轻度,结膜充血和/或出血在研究期间偶发。
  • 观察性随访中,角膜垂直纹对受累患者视觉功能无临床有意义影响。

临床怎么用

  • netarsudil 0.02%每日一次可作为开角型青光眼或高眼压的降眼压治疗选择,需关注结膜充血和角膜垂直纹等眼部不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). DESIGN: Double-masked, randomized, multicenter, parallel-group, noninferiority clinical study. METHODS: After a washout of all prestudy ocular hypotensive medications, 756 eligible patients with elevated IOP were randomized to receive netarsudil 0.02% once a day (q.d.) (251); netarsudil 0.02% twice a day (b.i.d.) (254); or timolol 0.5% b.i.d. (251) for 12 months, as well as a noninterventional Corneal Observation Study (COS) for patients manifesting cornea verticillata. RESULTS: On treatment, mean IOP at 8:00 AM decreased from a baseline IOP of 22.5-22.6 mm Hg to 17.9-18.8 mm Hg, 17.2-18.0 mm Hg, and 17.5-17.9 mm Hg for netarsudil q.d., netarsudil b.i.d., and timolol, respectively, over 12 months. The most frequently reported adverse events (AEs) were ocular, with the most frequent ocular AE being conjunctival hyperemia, with an incidence of 61%, 66%, and 14%, respectively. The next most frequent AEs were corneal deposits (corneal verticillata), with an incidence of 26%, 25%, and 1%, respectively, and conjunctival hemorrhage (typically petechial), with an incidence of 20%, 19%, and 1%, respectively. All 3 AEs were generally scored as mild, with conjunctival hyperemia and/or hemorrhage appearing sporadically during the study. In the observational follow-up component of this study, there was no clinically meaningful impact of corneal verticillata on visual function in affected patients. CONCLUSIONS: In this randomized, double-masked trial, once-daily dosing of netarsudil 0.02% was effective, consistently lowering IOP through 12 months, and was tolerated by the majority of patients.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kahook MY, Serle JB, Mah FS, et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol. 2019. PMID: 30653957. doi:10.1016/j.ajo.2019.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。